Clinical trial
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and…
NCT00324623 · Prof. Serge Leyvraz, Other · Completed
Key facts
| NCT number | NCT00324623 |
|---|---|
| Title | Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma |
| Official title | Phase I Study of In Vivo Expansion of Melan-A/MART-1 Antigen-Specific CD8 T Lymphocytes Following Transient Immunosuppression in Patients With Advanced Melanoma |
| Lead sponsor | Prof. Serge Leyvraz, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | Melan-A VLP vaccine, IMP321 adjuvant, adoptive immunotherapy, therapeutic autologous lymphocytes, cyclophosphamide, fludarabine phosphate |
| Enrollment | 8 |
| Start date | Sep 1, 2005 |
| Primary completion | Nov 1, 2011 |
| First posted | May 11, 2006 |
| Last update posted | Nov 20, 2012 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: